https://eureka.patsnap.com/resources/blog/rd-blog/lyophilized-biologic-formulation-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Biologics Formulation
Lyophilized Biologic Formulation Patents: Mapping the Field
  • Concentration is modest at the top. the five most active assignees hold 19.4% of all 9,460 records, and the ranked ten hold 30.6% — the rest is a long tail.
  • Filing has cooled from its peak. 2017 was the high-water mark at 549 records, and 2021-to-2024 filings fell 37%, from 494 to 311.
  • Claim activity is formulation-heavy, not analytics-heavy. A61K medicinal-preparation classes touch 87.9% of records, while material-analysis and testing claims (G01N) sit at just 2.9%.
Get a prior-art report on your approach
9,460
Published Records
19%
Top-5 Share of All Records
-37%
Filing Growth 2021→2024
US
Leading Jurisdiction

Filing growth compares 2021 (494 records) with 2024 (311) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 9,460 records in scope (CR5), not by the ranked leaders only.

Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Field Overview

What this patent set covers

Lyophilized biologic formulation sits at the intersection of drug product formulation and process engineering: how a protein, peptide or vector-based biologic is dried, stored and reconstituted without losing potency. The search underlying this landscape combines formulation language — lyophilized formulation, cake appearance, freeze drying cycle — with the process and quality variables that determine whether a cycle actually works at scale: collapse temperature, residual moisture, reconstitution time, annealing step, vial heterogeneity and cycle robustness.

The dataset spans 9,460 published records filed between 2015 and mid-2026. Because publication trails filing by roughly 18 months, the most recent one to two years understate real filing activity and should be read as provisional rather than a sign of decline.

Filing activity and technology composition, 2015–2026
  1. 1TAKEDA PHARMA CO LTD522
  2. 2BRISTOL MYERS SQUIBB CO406
  3. 3NOVARTIS AG360
  4. 4GENENTECH INC301
  5. 5F HOFFMANN LA ROCHE & CO AG250
  6. 6MERCK SHARP & DOHME LLC246
  7. 7SHIRE HUMAN GENETIC THERAPIES INC236
  8. 8REGENERON PHARMACEUTICALS INC206
  9. 9MILLENNIUM PHARMACEUTICALS INC191
  10. 10AMGEN INC178
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Lyophilized Biologic Formulation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Numbers

Filing trend and technology composition

Two views of the same 9,460-record corpus: how filing volume has moved year over year, and how claims distribute across IPC subclasses.

A 2017 peak followed by a multi-year pullback

Filings peaked in 2017 at 549 records. The 2021-to-2024 window, the last stretch with complete publication, shows a 37% decline from 494 to 311 records — a real contraction in new claim activity, not an artefact of publication lag.

A 2017 peak followed by a multi-year pullback0150300450600549201720182019202020212022202320242025362026Most recent year is partial — publication lag means later filings are not yet visible.

Formulation claims dominate; testing and analytics are thin

A61K (medicinal preparations) appears on 87.9% of records and C07K (peptides and proteins) on 32.9%, confirming this is primarily a formulation-composition field. G01N (material analysis and testing), C07D (heterocyclic compounds) and C07H (sugars and nucleic acids) each sit under 3%, which is thin given how central moisture and cake-structure analytics are to cycle development.

Formulation claims dominate; testing and analytics are thinA61K · Medicinal preparations8,31687.9%C07K · Peptides & proteins3,10832.9%A61P · Therapeutic activity of compou…3,06432.4%C12N · Microorganisms & genetic engin…1,22813.0%C12P · Fermentation & enzymatic synth…2893.1%G01N · Material analysis & testing2732.9%C07D · Heterocyclic compounds2672.8%C07H · Sugars & nucleic acids2292.4%Other1,59816.9%

Shares are the percentage of the 9,460 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.

Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Lyophilized Biologic Formulation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.

Go deeper on Lyophilized Biologic Formulation with Eureka

This page is one run against one query. Ask Eureka your own question about lyophilized biologic formulation and every answer comes back with the patent numbers behind it.

Try Eureka
Key Patents

A representative filing and the most-cited prior art

Representative Filing
US20090324586A12009-12-31

US20090324586A1 — Lyophilization cycle robustness strategy (Wyeth LLC, 2009-12-31)

WYETH LLC

The present invention provides methods for assessing and optimizing lyophilization cycle robustness. In particular, the present invention provides rapid assessment of cycle robustness with respect to a variety of lyophilization process deviations by varying a relatively small number of parameters.Framed as a process-robustness method rather than a composition claim, this filing sits upstream of formulation-specific patents — it constrains how cycle deviations are tested, not which excipients are used.

US20090324586A1 — patent drawing 1US20090324586A1 — patent drawing 2
View full filing
Most-cited records in this corpus
#Publication no.Patent titleCitations
1US6267958B1Protein formulation3,205
2WO1997004801A1Stabile isotonic lyophilized protein formulation1,403
3US5814482AEukaryotic layered vector initiation systems995
4WO1995007994A2Recombinant alphavirus vectors776
5WO1996017072A2Recombinant alphavirus vectors746
6US6685940B2Protein formulation621
7US5385887AFormulations for delivery of osteogenic proteins526
8US5843723AAlphavirus vector constructs511
9US5789245AAlphavirus structural protein expression cassettes495
10US20040197324A1High concentration antibody and protein formulations478

Citation counts accumulate over time and favour older filings; treat them as a signal of influence on later work, not of current commercial relevance.

Each row carries its publication number; clicking a row searches Eureka by that number.

Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Lyophilized Biologic Formulation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself

Put your own technology through the same analysis


  
Where to run it
Fastest

Eureka on the web

When you want the answer in the next five minutes.

The agent works the prompt against patents and technical literature, citing every source.

Run your analysis now →
For builders

MCP server & REST API

When it has to run inside your own pipeline.

Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.

Browse MCP servers →
Insights

What the data means for a filing strategy

Three findings that shape where new claims can still land and who is actively defending ground.

Concentration
19.4% / 30.6%
share held by top 5 / top 10 of 9,460 records

No single assignee controls the field

The leader holds 522 records against a corpus of 9,460, and even the combined top ten account for less than a third of all records. This is a field with a long tail of single- and few-filing entrants rather than a two- or three-way standoff.

Read as: room to file, not room to dominate.
Momentum
-37%
2021→2024 filings, 494 to 311

Volume is contracting among the largest filers

Recent-year momentum for the most active assignees is uniformly negative — several show year-on-year declines of 56% or more, and multiple leaders show zero filings in the latest year. That pattern, combined with the corpus-wide 2021-to-2024 drop, suggests consolidation of existing IP rather than fresh land-grabbing.

Provisional years (2025+) will fill in as publications catch up.
Composition
87.9% vs 2.9%
A61K share vs G01N share of 9,460 records

Analytics and testing claims are comparatively rare

Formulation composition (A61K) and biologic-specific classes (C07K, A61P) dominate claim activity. Material analysis and testing (G01N) sits at only 2.9% of records, despite residual moisture and cake-structure measurement being central to cycle validation — a gap between what the science requires and what has been claimed.

Analytics-adjacent claims remain comparatively open.
Eureka AI Agent
Looking for what nobody has claimed yet?

Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to lyophilized biologic formulation, with the prior art for and against each one.

Find the white space →
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Lyophilized Biologic Formulation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players

Who is filing, and where the gate sits

The ranked leaders in this dataset are large biologics originators — consistent with a field where formulation IP protects marketed products rather than platform technology.

Leader
522
records, leading assignee

One clear leader, no runaway gap

The top-ranked assignee holds 522 records, roughly double the fifth-place figure of 250 and nearly triple the tenth-place figure of 178 — a gradual taper rather than a cliff.

Consistent with a mature, actively defended portfolio.
Co-filing
10 pairs
co-assignee pairs identified

Co-assignee activity is limited and concentrated

Only ten co-assignee pairs appear in the dataset, and the strongest pairing far outweighs the others — most filers here protect formulation IP independently rather than through joint filings.

Joint-filing structures are the exception, not the norm.
Geography
1,734
US filings, the largest receiving office

Filing follows the major biologics markets

The United States leads receiving offices at 1,734, ahead of the EPO at 1,184 and WIPO/PCT filings at 867, with Australia, Israel and Canada each in the 500-to-800 range — a filing footprint that tracks major biologics regulatory markets rather than a single dominant jurisdiction.

Multi-jurisdiction filing is standard for this class of asset.
🔍
Under-claimed sub-areas worth a closer look
Branches where composition claims are dense but supporting process and analytics claims remain comparatively open.
Residual moisture measurement methodsAnnealing-step process controlsVial-to-vial heterogeneity detectionReconstitution time optimisationCake appearance / collapse temperature analytics
Rank all filers by momentum →
Recent-year filing momentum among leading assignees
AssigneeRecent yearYoY
Takeda Pharmaceutical Company Limited4-56%
Genentech, Inc.1-83%
Novartis AG0-100%
Bristol-Myers Squibb Company0-100%
Shire Human Genetic Therapies, Inc.0—
F. Hoffmann-La Roche AG0—
Millennium Pharmaceuticals, Inc.0-100%
Regeneron Pharmaceuticals, Inc.0-100%
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Lyophilized Biologic Formulation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next

Turning this landscape into a filing decision

The trend and composition data point to where claim space is open, but a filing decision needs claim-level comparison against the specific art in a target sub-area.

Check freedom-to-operate before drafting

Formulation composition claims are dense; a new filing needs to be checked against the specific excipient, buffer or lyoprotectant combination it covers, not just the broad category.

Run a freedom-to-operate check in Eureka

Watch the analytics gap

Testing and measurement claims (residual moisture, cake structure, vial heterogeneity) are comparatively thin relative to composition claims — a candidate area for new process-method filings.

Explore white space in Eureka

Track the largest filers' momentum

Several leading assignees show sharp year-on-year declines in filing volume; confirming whether that reflects portfolio maturity or a shift to trade secrecy changes how competitive that ground really is.

Monitor assignee activity in Eureka
Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Lyophilized Biologic Formulation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ

Common questions about this patent landscape

Answers are grounded in the same dataset. Derived from a Patsnap search on Lyophilized Biologic Formulation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Research Lyophilized Biologic Formulation in depth with Eureka

Go past this page: query the whole lyophilized biologic formulation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.

Try Eureka

Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.

Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.

Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.

Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.